A new breast cancer wonder drug has been approved for use in Australia from today.
Women diagnosed with the aggressive HER2+ breast cancer have a one in four chance of relapse, even after surgery and chemotherapy. Nerlynx reduces
the five-year risk of death or recurrence in women with early-stage HER2+ by 42 per cent.
For the moment the drug is available free via an access program.